NCT07076160

Brief Summary

This is a 6-visit, single-masked, multi-site, 2×3 crossover, randomized-controlled, dispensing clinical trial to evaluate visual acuity.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
74

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jul 2025

Shorter than P25 for not_applicable

Geographic Reach
1 country

7 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 14, 2025

Completed
8 days until next milestone

First Posted

Study publicly available on registry

July 22, 2025

Completed
2 days until next milestone

Study Start

First participant enrolled

July 24, 2025

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 20, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 20, 2025

Completed
Last Updated

April 13, 2026

Status Verified

April 1, 2026

Enrollment Period

2 months

First QC Date

July 14, 2025

Last Update Submit

April 9, 2026

Conditions

Outcome Measures

Primary Outcomes (3)

  • High Luminance, High Contrast (HLHC) Binocular logMAR Visual Acuity at distance (4 meters)

    Visual acuity after approximately 1-week in the optimized lens pair under HLHC illuminance conditions will be evaluated at distance (4 meters) using ETDRS Charts.

    1-week follow-up

  • High Luminance, High Contrast (HLHC) Binocular logMAR Visual Acuity at intermediate (64 cm)

    Visual acuity after approximately 1-week in the optimized lens pair under HLHC illuminance conditions will be evaluated at intermediate (64 cm) using reduced Guillon-Poling charts.

    1-week follow-up

  • High Luminance, High Contrast (HLHC) Binocular logMAR Visual Acuity at near (40 cm)

    Visual acuity after approximately 1-week in the optimized lens pair under HLHC illuminance conditions will be evaluated at near (40 cm) using reduced Guillon-Poling charts.

    1-week follow-up

Study Arms (2)

Test/Control/Control

EXPERIMENTAL

Eligible subjects will be randomized into the Test/Control/Control sequence.

Device: INFUSE® One Day MultifocalDevice: ACUVUE® OASYS MAX 1-Day Multifocal Contact Lens

Control/Test/Test

EXPERIMENTAL

Eligible subjects will be randomized into the Control/Test/Test sequence.

Device: INFUSE® One Day MultifocalDevice: ACUVUE® OASYS MAX 1-Day Multifocal Contact Lens

Interventions

Test Lens

Control/Test/TestTest/Control/Control

Control Lens

Control/Test/TestTest/Control/Control

Eligibility Criteria

Age40 Years - 70 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Potential subjects must satisfy all of the following criteria to be enrolled in the study: 1. Read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form. 2. Appear able and willing to adhere to the instructions set forth in this clinical protocol. 3. Be at least 40 years of age and not greater than 70 years of age at the time of consent. 4. Own a wearable pair of spectacles if required for their distance vision. 5. Be an adapted soft contact lens wearer in both eyes (i.e. worn lenses a minimum of 2 days per week for at least 6 hours per wear day, for 30 days or more duration). 6. Either already be wearing a presbyopic contact lens correction (e.g., reading spectacles over contact lenses, monovision or multifocal contact lenses, etc.) or if not respond positively to at least one symptom on the "Presbyopic Symptoms Questionnaire". 7. The subject's distance spherical equivalent refraction must be in the range of +1.00 to +4.00 or -1.00 D to -4.00 D in each eye. 8. The subject's refractive cylinder must be ≤0.75 D in each eye. 9. The subject's ADD power must be in the range of +0.75 D to +2.50 D. 10. The subject must have distance best corrected visual acuity of 20/20-3 or better in each eye. Potential subjects who meet any of the following criteria will be excluded from participating in the study: 1. Be currently pregnant or lactating. 2. Have any active or ongoing ocular or systemic allergies that may interfere with contact lens wear. 3. Have been diagnosed with diabetes. 4. Have any active or ongoing systemic disease, autoimmune disease, or use of medication, which may interfere with contact lens wear. This includes, but not be limited to, hyperthyroidism, Sjögren's syndrome, xerophthalmia, acne rosacea, Stevens-Johnson syndrome, and immunosuppressive diseases or any infectious diseases (e.g. hepatitis, tuberculosis). 5. Have any previous, or planned, ocular or intraocular surgery (e.g. radial keratotomy, PRK, LASIK, lid procedures, dacryocystorhinostomy, peripheral iridotomy/iridectomy, cataract surgery, retinal surgery, etc.). 6. Have a history of amblyopia, strabismus or binocular vision abnormality. 7. Use of any of the following medications within 1 week prior to enrollment: oral retinoid, oral tetracyclines, anticholinergics, oral phenothiazines, oral/inhaled corticosteroids. See section 9.1 for further examples. 8. Be currently using any ocular medications with the exception of rewetting drops. 9. Have a history of herpetic keratitis. 10. Have a history of irregular cornea. 11. Have a history of pathological dry eye. 12. Have participated in any contact lens or lens care product clinical trial within 7 days prior to study enrollment. 13. Be an employee (e.g., Investigator, Coordinator, Technician) or immediate family member of an employee (including partner, child, parent, grandparent, grandchild, sibling of the employee or their spouse) of the clinical site. 14. Have any known hypersensitivity or allergic reaction to non-preserved rewetting drop solutions or sodium fluorescein. 15. Have clinically significant (grade 3 or higher on the FDA grading scale) slit lamp findings (e.g., corneal edema, neovascularization or staining, tarsal abnormalities or bulbar injection) or other corneal or ocular disease or abnormalities that contraindicate contact lens wear or may otherwise compromise study endpoints (including entropion, ectropion, chalazia, recurrent styes, glaucoma, history of recurrent corneal erosions, aphakia, moderate or above corneal distortion, herpetic keratitis). 16. Have any current ocular infection or inflammation.

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

Study Sites (7)

Dr. James Weber & Associates, PA - City Square Blvd

Jacksonville, Florida, 32218, United States

Location

VRC

Jacksonville, Florida, 32256, United States

Location

Pearson Research Center, PA

Longwood, Florida, 32779, United States

Location

Maitland Vision Center - North Orlando Ave

Maitland, Florida, 32751, United States

Location

Sacco Eye Group

Vestal, New York, 13850, United States

Location

Luxe Vision and Optical

Powell, Ohio, 43065, United States

Location

Dr. David W. Ferris & Associates

Warwick, Rhode Island, 02888, United States

Location

MeSH Terms

Conditions

Presbyopia

Condition Hierarchy (Ancestors)

Refractive ErrorsEye Diseases

Study Officials

  • Johnson & Johnson Vision Care, Inc. Clinical Trial

    Johnson & Johnson Vision Care, Inc.

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 14, 2025

First Posted

July 22, 2025

Study Start

July 24, 2025

Primary Completion

September 20, 2025

Study Completion

September 20, 2025

Last Updated

April 13, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will share

Johnson \& Johnson Medical Device Companies have an agreement with the Yale Open Data Access (YODA) to serve as the independent review panel for evaluation of requests for clinical study reports and participant level data from investigators and physicians for scientific research that will advance medical knowledge and public health. Requests for access to the study data can be submitted through the YODA Project site at http://yoda.yale.edu

More information

Locations